Cases of the chronic liver condition, MAFLD, and its progressive form, MASH, are on the increase, yet there are currently no approved treatments for these conditions.
A key barrier to pharmaceutical development is the poor translation of pre-clinical models to the human environment, with drug candidates failing to reach clinical endpoint at trial stages.
In this case study, we discuss how the PXB-mouse® model was used to retrospectively test elafibranor, a potential MASH drug candidate that failed to meet its primary clinical endpoint in Phase III trials.
Simply fill out the form to get your copy.